RESUMO
BACKGROUND: While it is acknowledged that child obesity interventions should cover multiple ecological levels (downstream, midstream and upstream) to maximize their effectiveness, there is a lack of evaluation data to guide the development and implementation of such efforts. To commence addressing this knowledge gap, the present study provides process evaluation data relating to the experiences of groups implementing the EPODE approach to child obesity prevention in various locations around the world. The aim of this exploratory study was to investigate the barriers and facilitators to program implementation in program sites around the world to assist in developing strategies to enhance program outcomes. METHODS: An online survey that included open-ended questions was distributed to the 25 EPODE programs in operation at the time of the survey (May 2012). The survey items asked respondents to comment on those aspects of program implementation that they found challenging and to suggest areas for future improvement. Eighteen programs representing 14 countries responded to the request to participate in the survey, yielding a 72% response rate. The responses were analyzed via the constant comparative method using NVivo qualitative data analysis software. RESULTS: The main concerns of the various EPODE programs were their ability to secure ongoing funding and their access to evidence-based intervention methods and policy advice relating to relationships with third parties. These issues were in turn impacted by other factors, including (i) access to user-friendly information relating to the range of intervention strategies available and appropriate evaluation measures; (ii) assistance with building and maintaining stakeholder relationships; and (iii) assurance of the quality, independence, and transparency of policies and practices. CONCLUSIONS: The findings are facilitating the ongoing refinement of the EPODE approach. In particular, standardized and tailored information packages are being made available to advise program members of (i) the various evaluation methods and tools at their disposal and (ii) methods of acquiring private partner support. Overall, the study results relating to the types of issues encountered by program members are likely to be useful in guiding the future design and implementation of multi-level initiatives seeking to address other complex and intractable health-related problems.
Assuntos
Internacionalidade , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Obesidade Infantil/prevenção & controle , Avaliação de Programas e Projetos de Saúde/estatística & dados numéricos , Criança , Feminino , Humanos , Masculino , Inquéritos e QuestionáriosRESUMO
OBJECTIVES: We examined racial/ethnic disparities in highly active antiretroviral therapy (HAART) use and whether differences are moderated by substance use or insurance status, using data from the Women's Interagency HIV Study (WIHS). METHODS: Logistic regression examined HAART use in a longitudinal cohort of women for whom HAART was clinically indicated in 2005 (N = 1354). RESULTS: Approximately 3 of every 10 eligible women reported not taking HAART. African American and Hispanic women were less likely than were White women to use HAART. After we adjusted for potential confounders, the higher likelihood of not using HAART persisted for African American but not for Hispanic women. Uninsured and privately insured women, regardless of race/ethnicity, were less likely than were Medicaid enrollees to use HAART. Although alcohol use was related to HAART nonuse, illicit drug use was not. CONCLUSIONS: These findings suggest that expanding and improving insurance coverage should increase access to antiretroviral therapy across racial/ethnic groups, but it is not likely to eliminate the disparity in use of HAART between African American and White women with HIV/AIDS.
Assuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV , Seguro Saúde/economia , Adesão à Medicação/etnologia , Transtornos Relacionados ao Uso de Substâncias/etnologia , Adulto , Negro ou Afro-Americano/etnologia , Terapia Antirretroviral de Alta Atividade/economia , Terapia Antirretroviral de Alta Atividade/estatística & dados numéricos , Estudos Transversais , Feminino , Seguimentos , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Infecções por HIV/etnologia , Pesquisas sobre Atenção à Saúde , Acessibilidade aos Serviços de Saúde , Disparidades em Assistência à Saúde , Hispânico ou Latino/etnologia , Humanos , Cobertura do Seguro/economia , Modelos Logísticos , Medicaid/estatística & dados numéricos , Pessoas sem Cobertura de Seguro de Saúde/estatística & dados numéricos , Adesão à Medicação/estatística & dados numéricos , Pessoa de Meia-Idade , Análise Multivariada , Fatores Socioeconômicos , Transtornos Relacionados ao Uso de Substâncias/complicações , Estados Unidos/epidemiologia , População Branca/etnologiaRESUMO
Any reformed health care system must be able to react to and mitigate the consequences of a public health emergency. This article identifies four essential components of public health emergency preparedness, and presents measures that can be taken immediately to improve our capacity to respond to emergencies.
Assuntos
Defesa Civil/organização & administração , Planejamento em Desastres/organização & administração , Reforma dos Serviços de Saúde/organização & administração , Saúde Pública/métodos , Defesa Civil/métodos , Planejamento em Desastres/normas , Reforma dos Serviços de Saúde/normas , Humanos , Saúde Pública/normas , Estados UnidosRESUMO
This JAMA Forum discusses innovative efforts in various states to improve public health by providing more funding and programs with input and support for reform from local residents, businesses, and community organizations.
Assuntos
Saúde PúblicaRESUMO
The Centers for Disease Control and Prevention estimates that of the approximately 1.2 million people with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome in the United States, approximately 500,000 are not receiving care for their disease, including approximately 250,000 who do not know they are HIV positive. Although little is known about these 2 subgroups of HIV-infected people, they are likely to be reflective of the larger population of people with HIV infection; that is, they are predominantly racial minorities, more likely to be unemployed and/or poor, and much more likely to be uninsured or dependent on public insurance programs such as Medicaid, compared with the US population overall. In addition, many persons receive a diagnosis of HIV infection late during the course of the disease, and those who are difficult to reach are less likely to receive standard-of-care antiretroviral therapy. New testing initiatives attempting to diagnose infection in persons who do not know their HIV infection status have raised important questions about the funding and program capacity of the current system to handle new patients. Given these challenges and questions, measuring the success of new testing initiatives will be critical but difficult.
Assuntos
Sorodiagnóstico da AIDS/economia , Serviços de Diagnóstico/estatística & dados numéricos , Infecções por HIV , Acessibilidade aos Serviços de Saúde , Cobertura do Seguro/estatística & dados numéricos , Seguro Saúde/estatística & dados numéricos , Sorodiagnóstico da AIDS/estatística & dados numéricos , Antirretrovirais/uso terapêutico , Feminino , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde , Humanos , Masculino , Gravidez , Complicações Infecciosas na Gravidez/diagnóstico , Saúde Pública , Fatores de Risco , Fatores SocioeconômicosRESUMO
Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
Assuntos
Buprenorfina/uso terapêutico , Prestação Integrada de Cuidados de Saúde/economia , Infecções por HIV/tratamento farmacológico , Recursos em Saúde , Antagonistas de Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Terapia Antirretroviral de Alta Atividade/economia , Buprenorfina/economia , Prestação Integrada de Cuidados de Saúde/métodos , Feminino , Financiamento Governamental , Infecções por HIV/diagnóstico , Infecções por HIV/economia , Custos de Cuidados de Saúde , Política de Saúde , Humanos , Reembolso de Seguro de Saúde/economia , Masculino , Antagonistas de Entorpecentes/economia , Transtornos Relacionados ao Uso de Opioides/diagnóstico , Transtornos Relacionados ao Uso de Opioides/economia , Atenção Primária à Saúde/economia , Qualidade da Assistência à Saúde , Estados UnidosRESUMO
This article documents the instability and variation in public financing of public health functions at the federal and state levels. Trust for America's Health has charted federal funding for the Centers of Disease Control and Prevention, which in turn provides a major portion of financing for state and local public health departments, and has compiled information about state-generated revenue commitments to public health activities nationwide. The federal-level analysis shows that funding has been marked by diminished support for "core" public health functions. The state-level analysis shows tremendous variation in use of state revenues to support public health functions. The combination of these factors results in very different public health capacities across the country, potentially leaving some states more vulnerable, while simultaneously posing a general threat to the nation since public health problems do not honor state borders. On the basis of this analysis, the authors suggest changes in the financing arrangements for public health, designed to assure a more stable funding stream for core public health functions and a more consistent approach to financing public health activities across the country.